MerckLIM:MRK 71 EBITDA Margin % is -9.47% as of Mar. 2026. GuruFocus rates LIM:MRK with a GF Score™ of 71/100 and a GF Value™ of $113.28 (Fairly Valued). The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Merck ranks better than 85.24% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Merck's EBITDA for the
three
months ended in Mar. 2026 was $-1,543 Mil. Merck's Revenue for the
three
months ended in Mar. 2026 was $16,286 Mil. Therefore, Merck's EBITDA margin for the quarter that ended in Mar. 2026 was -9.47%.
Merck (LIM:MRK) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Merck EBITDA Margin % Related Terms
Merck EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Merck's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LIM:MRK vs ABBV, AMGN, GILD: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Merck's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merck EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Merck's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Merck's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merck (LIM:MRK) has a EBITDA Margin % of -9.47% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Merck and its competitors. Over the past decade, Merck's EBITDA Margin % has ranged from 11.49 to 43.47. According to the industry distribution chart, Merck ranks #141 out of 955 companies in the Drug Manufacturers industry, placing it in the top 14.8%.
Is Merck's EBITDA Margin % too high?
Merck's current EBITDA Margin % is -9.47%. Over the past 10 years, this metric has ranged from a low of 11.49 to a high of 43.47. Based on the distribution chart, Merck ranks #141 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Merck has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck's EBITDA Margin % compare to ABBV and AMGN?
According to the Drug Manufacturers industry distribution chart, Merck ranks #141 out of 955 companies for EBITDA Margin %. This places Merck in the top 15% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Historically, Merck's own EBITDA Margin % has ranged from 11.49 to 43.47 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Merck and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Merck's current EBITDA Margin % is -9.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Based on GuruFocus' analysis, Merck (LIM:MRK) is currently considered Fairly Valued. The stock's GF Value™ is $113.28, compared to a current price of $120.00 — trading 5.9% above its estimated fair value. The current EBITDA Margin % is -9.47%. Merck's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Merck (LIM:MRK), the current EBITDA Margin % is -9.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Merck (LIM:MRK) Overvalued in 2026?
Based on GuruFocus' analysis, Merck stock appears to be overvalued.
The current stock price of $120.00 is trading 5.9% above its estimated GF Value™ of $113.28.
GuruFocus considers Merck to be Fairly Valued.
Key valuation signals for LIM:MRK:
EBITDA Margin %: -9.47%
GF Value™: $113.28 vs. price of $120.00 (5.9% above fair value)
No single metric tells the full story. See the LIM:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
71GF Score
Get the complete analysis for LIM:MRK
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIM:MRK has been successfully added to your 
